• 1
    DeVore RF, Johnson DH, Crawford J, et al. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 1999; 17: 27102720.
  • 2
    Masuda N, Fukuoka M, Fujita A, et al. A Phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group. Br J Cancer. 1998; 78: 251256.
  • 3
    Negoro S, Masuda N, Takada Y, et al. Randomised Phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer. 2003; 88: 335341.
  • 4
    Mori K, Machida S, Yoshida T, Yoshida M, Kano Y, Tominaga K. A Phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 1999; 43: 467470.
  • 5
    Ueoka H, Tanimoto M, Kiura K, et al. Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a Phase II study of Okayama Lung Cancer Study Group. Br J Cancer. 2001; 85: 913.
  • 6
    Jagasia MH, Langer CJ, Johnson DH, et al. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter Phase II study. Clin Cancer Res. 2001; 7: 6873.
  • 7
    Saltz LB, Spriggs D, Schaaf LJ, et al. Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. J Clin Oncol. 1998; 16: 38583865.
  • 8
    Masumoto N, Nakano S, Esaki T, Fujishama H, Tatsumoto T, Niho Y. Inhibition of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells. Int J Cancer. 1995; 62: 7075.
  • 9
    Fukuda M, Nishio K, Kanzawa F, et al. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res. 1996; 56: 789793.
  • 10
    Ma J, Maliepaard M, Nooter K, et al. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol. 1998; 41: 307316.
  • 11
    Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988; 48: 17221726.
  • 12
    Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y. Structure-activity study of the actions of campthotecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relaxation to antitumor activity. Cancer Res. 1989; 49: 14651469.
  • 13
    Crul M, van Waardenburg RC, Beijnen JH, Schellens JH. DNA-based drug interactions of cisplatin. Cancer Treat Rev. 2002; 28: 291303.
  • 14
    Kanzawa F, Koizumi F, Koh Y, et al. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin Cancer Res. 2001; 7: 202209.
  • 15
    Goldwasser F, Valenti M, Torres R, Kohn KW, Pommier Y. Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clin Cancer Res. 1996; 2: 687693.
  • 16
    World Health Organization. WHO handbook for reporting results of cancer treatment. WHO Offset Pub No. 48. Geneva: World Health Organization, 1979.
  • 17
    de Bruijn P, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl. 1997; 698: 277285.
  • 18
    A'Hern RP. Sample size tables for exact single-stage Phase II designs. Stat Med. 2001; 20: 859866.
  • 19
    de Jong FA, Mathijssen RH, Xie R, Verweij J, Sparreboom A. Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res. 2004; 10: 40684071.
  • 20
    Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004; 22: 330353.
  • 21
    Hilsenbeck SG, Raub WA Jr., Sridhar KS. Prognostic factors in lung cancer based on multivariate analysis. Am J Clin Oncol. 1993; 16: 301309.
  • 22
    Ries LA. Influence of extent of disease, histology, and demographic factors on lung cancer survival in the SEER population-based data. Semin Surg Oncol. 1994; 10: 2130.
  • 23
    Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol. 2005; 23: 175183.
  • 24
    Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001; 7: 21822194.
  • 25
    Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004; 22: 13821388.
  • 26
    Gupta E, Lestingi TM, Mick R, et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 1994; 54: 37233725.
  • 27
    Gupta E, Mick R, Ramirez J, et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol. 1997; 15: 15021510.